Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Consolidated Net Income: 2020-2025

Historic Consolidated Net Income for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$2.3 million.

  • Journey Medical's Consolidated Net Income rose 3.14% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year increase of 53.41%. This contributed to the annual value of -$14.7 million for FY2024, which is 280.79% down from last year.
  • As of Q3 2025, Journey Medical's Consolidated Net Income stood at -$2.3 million, which was up 38.04% from -$3.7 million recorded in Q2 2025.
  • Journey Medical's Consolidated Net Income's 5-year high stood at $16.8 million during Q3 2023, with a 5-year trough of -$21.8 million in Q4 2021.
  • In the last 3 years, Journey Medical's Consolidated Net Income had a median value of -$3.4 million in 2024 and averaged -$2.6 million.
  • As far as peak fluctuations go, Journey Medical's Consolidated Net Income tumbled by 36,810.34% in 2021, and later spiked by 266.56% in 2023.
  • Journey Medical's Consolidated Net Income (Quarterly) stood at -$21.8 million in 2021, then surged by 51.07% to -$10.6 million in 2022, then surged by 79.86% to -$2.1 million in 2023, then surged by 173.82% to $1.6 million in 2024, then climbed by 3.14% to -$2.3 million in 2025.
  • Its Consolidated Net Income was -$2.3 million in Q3 2025, compared to -$3.7 million in Q2 2025 and -$4.1 million in Q1 2025.